-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Chia Tai Tianqing Pharmaceutical Co.
, Ltd.
's Class 1 new drug TQH3910 tablets was applied for clinical application in China for the first time
.
According to data from Minai.
com, since this year, CP Tianqing Pharmaceuticals has submitted 22 new drugs for marketing/clinical applications, of which 17 are Class 1 new drugs (15 are the first applications)
.
Source: CDE official website On December 14, the clinical application for TQH3910 tablets submitted by Chia Tai Tianqing as a new drug category 1 was accepted by the CDE, with the acceptance numbers CXHL2101750 and CXHL2101751
.
After years of development, CP Tianqing Pharmaceutical has gradually moved from "combination of imitation and innovation" to "combination of innovation and imitation", and rapid progress has been made in the research and development of innovative drugs
.
According to data from Meinenet, since 2021, CP Tianqing Pharmaceuticals has submitted 22 new drug listing/clinical applications (including new indications), of which 2 are biosimilar drugs and 17 are Class 1 new drugs
.
From the perspective of the treatment field, anti-tumor drugs are the mainstay
.
From 2021 to the present, the source of new drugs submitted by Chia Tai Tianqing for listing/clinical applications: Meinenet MED2.
0 China Drug Evaluation Database 15 Class 1 new drugs were first applied for clinical clinical application in China, 13 of which have been approved for clinical trials, TQB3617 capsules, TQA3605 Tablets, TQB2825, TQB3811 tablets, TQB3909 tablets, TQB3823 tablets, TQB3824 tablets, TQB3820 tablets, TQC2731 injection, and TQC3721 suspension for inhalation have started clinical trials and are currently in phase I clinical trials
.
Among the two biosimilar drugs, bevacizumab injection has been reported for production.
The terminal sales of this product in China's public medical institutions exceeded 3 billion yuan in the first half of 2021.
There are currently 8 domestic companies offering bevacizumab.
Biosimilar drugs are approved; the company is the first company to submit a clinical application for mepolizumab injection, and the global sales of the original research product in 2020 will reach 994 million pounds
.
Source: Mi Nei.
com database, CDE official website, etc.
Note: Statistics are as of December 15th.
If there are any omissions, please correct me!
, Ltd.
's Class 1 new drug TQH3910 tablets was applied for clinical application in China for the first time
.
According to data from Minai.
com, since this year, CP Tianqing Pharmaceuticals has submitted 22 new drugs for marketing/clinical applications, of which 17 are Class 1 new drugs (15 are the first applications)
.
Source: CDE official website On December 14, the clinical application for TQH3910 tablets submitted by Chia Tai Tianqing as a new drug category 1 was accepted by the CDE, with the acceptance numbers CXHL2101750 and CXHL2101751
.
After years of development, CP Tianqing Pharmaceutical has gradually moved from "combination of imitation and innovation" to "combination of innovation and imitation", and rapid progress has been made in the research and development of innovative drugs
.
According to data from Meinenet, since 2021, CP Tianqing Pharmaceuticals has submitted 22 new drug listing/clinical applications (including new indications), of which 2 are biosimilar drugs and 17 are Class 1 new drugs
.
From the perspective of the treatment field, anti-tumor drugs are the mainstay
.
From 2021 to the present, the source of new drugs submitted by Chia Tai Tianqing for listing/clinical applications: Meinenet MED2.
0 China Drug Evaluation Database 15 Class 1 new drugs were first applied for clinical clinical application in China, 13 of which have been approved for clinical trials, TQB3617 capsules, TQA3605 Tablets, TQB2825, TQB3811 tablets, TQB3909 tablets, TQB3823 tablets, TQB3824 tablets, TQB3820 tablets, TQC2731 injection, and TQC3721 suspension for inhalation have started clinical trials and are currently in phase I clinical trials
.
Among the two biosimilar drugs, bevacizumab injection has been reported for production.
The terminal sales of this product in China's public medical institutions exceeded 3 billion yuan in the first half of 2021.
There are currently 8 domestic companies offering bevacizumab.
Biosimilar drugs are approved; the company is the first company to submit a clinical application for mepolizumab injection, and the global sales of the original research product in 2020 will reach 994 million pounds
.
Source: Mi Nei.
com database, CDE official website, etc.
Note: Statistics are as of December 15th.
If there are any omissions, please correct me!
